nonavalent HPV vaccine / Wantai BioPharm - LARVOL DELTA

Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women (clinicaltrials.gov) - P=N/A | N=392 | Active, not recruiting | Sponsor: Xiamen University | Trial completion date: Mar 2025 ➔ Sep 2025

Trial completion date • Cervical Cancer • Oncology • Solid Tumor

Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women (clinicaltrials.gov) - P=N/A | N=392 | Active, not recruiting | Sponsor: Xiamen University | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Dec 2024 ➔ Mar 2025 | Trial primary completion date: Mar 2024 ➔ Mar 2025

Enrollment closed • Trial completion date • Trial primary completion date • Cervical Cancer • Oncology • Solid Tumor

Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women (clinicaltrials.gov) - P=N/A | N=392 | Not yet recruiting | Sponsor: Xiamen Ophthalmology Center Affiliated to Xiamen University

New trial • Cervical Cancer • Oncology • Solid Tumor

An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old (clinicaltrials.gov) - P3 | N=1382 | Active, not recruiting | Sponsor: Xiamen Ophthalmology Center Affiliated to Xiamen University | Trial completion date: Dec 2023 ➔ Dec 2025 | Trial primary completion date: Dec 2023 ➔ Dec 2025

Head-to-Head • Trial completion date • Trial primary completion date • Cervical Cancer • Oncology • Ovarian Cancer • Solid Tumor

Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age (clinicaltrials.gov) - P3 | N=488 | Completed | Sponsor: Xiamen University | Active, not recruiting ➔ Completed | Trial completion date: Dec 2022 ➔ Jul 2022

Trial completion • Trial completion date • Cervical Cancer • Oncology • Solid Tumor

An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old (clinicaltrials.gov) - P3 | N=1382 | Active, not recruiting | Sponsor: Xiamen University | Trial primary completion date: Dec 2022 ➔ Dec 2023

Head-to-Head • Trial primary completion date • Cervical Cancer • Oncology • Ovarian Cancer • Solid Tumor